Maria Sundvall
MD PhD; Specialist Physician in Clinical Oncology
mahesu@utu.fi Kiinamyllynkatu 10 Turku |
Areas of expertise
clinical oncology; breast and prostate cancer; targeted cancer therapeutics; cancer biology; cell signaling; posttranslational modifications; dna repair pathways
clinical oncology; breast and prostate cancer; targeted cancer therapeutics; cancer biology; cell signaling; posttranslational modifications; dna repair pathways
Biography
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Research
Dr. Sundvall has 20 years of experience in studying molecular mechanisms of cancer. Currently she is a principal investigator at University of Turku, and her group is focusing on investigating the role fo DNA repair pathways in prostate cancer. Links:
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
Teaching
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
Publications 
2 of 2
- A metabolic prosurvival role for PML in breast cancer (2012)
- Journal of Clinical Investigation
(A1 Refereed original research article in a scientific journal) - Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein (2012)
- Journal of Biological Chemistry
(A1 Refereed original research article in a scientific journal) - Function of ERBB4 is determined by alternative splicing. (2011)
- Cell Cycle
(A1 Refereed original research article in a scientific journal) - Cell Death or Survival Promoted by Alternative Isoforms of ErbB4 (2010)
- Molecular Biology of the Cell
(A1 Refereed original research article in a scientific journal) - EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma (2010)
- Expert Opinion on Emerging Drugs
(A2 Refereed review article in a scientific journal ) - Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro (2009)
- Radiotherapy and Oncology
(A1 Refereed original research article in a scientific journal) - Pim-1 Kinase Expression Predicts Radiation Response in Squamocellular Carcinoma of Head and Neck and Is under the Control of Epidermal Growth Factor Receptor (2009)
- Neoplasia
(A1 Refereed original research article in a scientific journal) - Somatic mutations of ErbB4: Selective loss-of-function phenotype affecting signal transduction pathways in cancer (2009)
- Journal of Biological Chemistry
(A1 Refereed original research article in a scientific journal) - Role of ErbB4 in breast cancer (2008)
- Journal of Mammary Gland Biology and Neoplasia
(A2 Refereed review article in a scientific journal ) - Association of Wwox with ErbB4 in breast cancer (2007)
- Cancer Research
(A1 Refereed original research article in a scientific journal) - Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro (2007)
- Radiotherapy and Oncology
(A1 Refereed original research article in a scientific journal) - Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains (2007)
- Oncogene
(A1 Refereed original research article in a scientific journal) - Proteolytic cleavage and phosphorylation of tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. (2006) Määttä J.A., Sundvall M., Junttila T.T., Peri L., Isola J., Egeblad M., Elenius K.
(A1 Refereed original research article in a scientific journal) - Signaling via ErbB2 and ErbB3 associates with resistance and Epidermal Growth Factor Receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells (2006)
- Clinical Cancer Research
(A1 Refereed original research article in a scientific journal) - Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells (2005)
- Cancer Research
(A1 Refereed original research article in a scientific journal) - Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor (2003) Iivanainen E, Nelimarkka L, Elenius V, Heikkinen S-M, Junttila TT, Sihombin L, Sundvall M, Määttä JA, Laine VJO, Higashiyama S, Alitalo K, Elenius K
(A1 Refereed original research article in a scientific journal) - A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis (2000) Kainulainen V, Sundvall M, Määttä JA, Santiestevan E, Klagsbrun M, Elenius K
(A1 Refereed original research article in a scientific journal) - Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants (2000) Junttila TT, Sundvall M, Määttä JA, Elenius K
(A1 Refereed original research article in a scientific journal)
UTU Research Portal